BioSpace News Archive

Osprey Medical (ASX: OSP) is pleased to announce the launch of DyeMINISH™; a global patient registry to evaluate the ongoing safety and performance of the DyeVert™ Contrast Reduction System during standard clinical use in a real-world patient population.

Greene Tweed’s Fusion™ FKM 665, a new generation, ultra-low-temperature and chemical-resistant elastomer, was specifically formulated to meet and exceed the requirements of Aerospace Material Specification (AMS) 7379 and AMS-P-83461.

Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs that address treatment resistance, and Almac Diagnostic Services, a global stratified medicine company, today announced approval by the U.S. Food and Drug Administration (FDA) of an investigational device exemption (IDE) for the diagnostic assay that will be used in Turning Point’s registrational phase 2 clinical study.

Veltassa® (patiromer) enables spironolactone for blood pressure management in patients with resistant hypertension and chronic kidney disease by controlling blood potassium levels.

Hill to Lead Effort to Increase Access to Clinical Studies

On September 18, 2018 Episcopal Health Services became aware of suspicious activity in employee email accounts.

Vireo Health International, Inc. (“Vireo” or the “Company”) (CSE: VREO), a leading science-focused, multi-state cannabis company, today announced its participation at the 3rd Annual Canaccord Genuity Cannabis Conference in New York City on May 14, 2019.

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results of a new, retrospective, observational study showing 49 percent of patients with type 2 diabetes (T2D) and lab-confirmed chronic kidney disease (CKD) did not have a CKD diagnosis from their doctor in a claims database.

The Pennsylvania Mesothelioma Victims Center is offering a person with mesothelioma or asbestos exposure lung cancer anywhere in Pennsylvania direct access to attorney Erik Karst and his remarkable team at the law firm of Karst von Oiste to ensure a superior compensation settlement.

The Alzheimer’s Clinical Trials Consortium (ACTC) and Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the investigational oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: E2609) and the investigational anti-amyloid beta (Ab) protofibril antibody BAN2401, have been selected by the ACTC